patients

Manipal Hospitals Kolkata completes 50 successful TAVR cases

KOLKATA, India, Aug. 12, 2025 /PRNewswire/ -- Manipal Hospitals - EM Bypass (erstwhile Medica Superspecialty Hospital), Kolkata is thrilled to announce…

2 days ago

Anteris Announces Results for the Second Quarter of 2025

MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR,…

3 days ago

Anbogen Receives FDA Clearance to Initiate Phase 1/2 Trial of ABT-301 Triplet Therapy for Advanced Colorectal Cancer

TAIPEI, Aug. 4, 2025 /PRNewswire/ -- Anbogen Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved…

5 days ago

Everhope Oncology Launches First Cancer Daycare Centre in Gurugram — Revolutionizing Cancer Care with Compassion, Precision and Convenience

Everhope Oncology takes the anxiety out of cancer treatment — with zero wait time, 2X faster service, pre-booked diagnostics, and…

7 days ago

Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA

AHMEDABAD, India, Aug. 6, 2025 /PRNewswire/ -- Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, has…

1 week ago

Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Mechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today…

1 week ago

Aicuris Presents Pharmacokinetic Data from the First-in-Human Clinical Trial of AIC468, a Novel Antisense Oligonucleotide Targeting BK Virus, at World Transplant Congress

Initial results from the First in Human (FIH) Phase 1 trial evaluating AIC468, a 2nd generation antisense oligonucleotide (ASO), in…

1 week ago

Kyowa Kirin Announces Abstract Presentation at the European Academy of Dermatology and Venereology (EADV) Congress

PRINCETON, N.J. and TOKYO, July 29, 2025 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of…

2 weeks ago

FDA Approves Apellis EMPAVELI (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

Proven efficacy across all three key markers of disease—68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of…

2 weeks ago

Shanton Receives Fast Track Designation from US FDA for Refractory Gout Program

SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., July 25,…

3 weeks ago